Window Study of ZD4054 in Metastatic Prostate Cancer
Status:
Unknown status
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective study in which patients with castrate-resistant prostate cancer and
bone metastases will undergo imaging, donate blood, bone marrow and urine samples, and where
possible primary tumour and bone metastatic tissue, before and during treatment with ZD4054,
an orally active specific endothelin-A antagonist. The samples will be used primarily for
biomarker studies, and it is hypothesized that these will inform on the mechanism of action
of this drug. Magnetic Resonance Imaging (MRI) will be performed to evaluate emerging
functional imaging endpoints as markers of early response in bone metastatic prostate cancer.